Trial Profile
Pilot Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Cysteamine Bitartrate Delayed-release Capsules (RP103), Compared to Cysteamine Bitartrate (Cystagon) in Patients With Nephropathic Cystinosis
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Mercaptamine bitartrate (Primary)
- Indications Nephropathic cystinosis
- Focus Adverse reactions
- Sponsors Raptor Pharmaceutical Inc
- 24 Oct 2014 As per NCT record phase changed from I to I/II and primary end point changed from safety and tolerability to Pk and PD and respective time frame got decreased.
- 26 Jun 2014 New trial record